BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health virtual conference, Wednesday, February 3-4

Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Rapid Acoustic Pulse (“RAP”) technology for the short-term improvement in the appearance of cellulite.

FEops, a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide™ for the pre-operative planning of structural heart interventions.

Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team.

The financing will be used to advance its AI-guided laser platform to automate and scale autologous cell-and tissue-based therapies.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that it has named Dr. Jon Nels Peterson a Senior Scientist in its Medical & Health Informatics (MEI) Lab.

Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of preclinical data demonstrating that KD033, the Companys anti-PD-L1/IL-15 fusion protein, achieved robust anti-tumor responses in multiple syngeneic tumor models.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Sciences is increasing its ownership in Arcus to 19.5%, from approximately 13%, by purchasing 5,650,000 additional shares of Arcus’s common stock at a per share purchase price of $39.00.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and Drug Administration to market a generic version of GOCOVR